CA
NZ
UK
AU
IND
US
The device maker also benefited from a wider move after Democrats won control of Congress, which eased political uncertainty and lifted health stocks. Peers including Medtronic (NYSE:MDT) and Intuitive Surgical (NASDAQ:ISRG) advanced in the same session, and theDow Jones Industrial Averagewas up about 2.9%.
The largest capitated contract drove 10.7 points of organic growth, and itsMarginrose to about 10% from negative 4% in the second quarter, exiting the quarter near 14%. Management targets a 20% margin on that contract by the fourth quarter of next year. RBC reiterated …
In a poorly immunogenic, fast-growing B16F10 melanoma model, daily oral elraglusib significantly slowed tumor growth and was well tolerated. Tumor analysis showed more CD8+ T cells and natural killer cells and fewer myeloid-like suppressor cells, which suggests the treatment shifts the tumor environment toward …
Investors seem to be weighing a flat implied fourth quarter, a decline expected in service revenue, a wider operating loss and the planned retirement of an executive.
The initial after-hours reaction to the results was muted, but analysts moved quickly. UBS raised its target to $530, Goldman Sachs to $536, TD Cowen to $531 and Oppenheimer to $520.
Third-quarter results are due, with sources differing on whether they arrive after today’s close or on Thursday.
In a concurrent private placement, the company will issue warrants to buy up to 2,962,500 more shares at $1.70 each. The warrants become exercisable six months after issuance and expire five and a half years from the issue date. Gross proceeds are expected to …
A roughly $175 million non-cash goodwill impairment in the Bruker Spatial BiologyBusinesspushed GAAP results to a loss of $0.81 per share. Investors are looking past it, given the improvement in underlying profitability and cash flow. FreeCash Flowrose $151 million from a year earlier, $58 …
A broad rally in health stocks after the midterms added a tailwind, though a gain of this size is clearly specific to the stock.
J.P. Morgan cautioned that gridlock and veto power make major reform unlikely, so the group is trading more on reduced risk than new rules.
Please wait processing your request...